Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17265934 | MODULATING PTPN2 TO INCREASE IMMUNE RESPONSES AND PERTURBING GENE EXPRESSION IN HEMATOPOIETIC STEM CELL LINEAGES | Final Rejection | President and Fellows of Harvard College |
| 17999352 | ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17595015 | NON-HLA MARKERS OF TRANSPLANT REJECTION | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17767818 | RECOMBINANT POLYPEPTIDES FOR REGULATABLE CELLULAR LOCALIZATION | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17149541 | USE OF INHIBITORY CHIMERIC RECEPTORS TO PREVENT T CELL-INDUCED BLOOD BRAIN BARRIER DAMAGE | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18155510 | HISTAMINE AND HRH1 SIGNALING ACTIVITY AS BIOMARKERS AND ASSOCIATED METHODS | Non-Final OA | Board of Regents, The University of Texas System |
| 18256853 | TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18056907 | MULTISPECIFIC BINDING MOIETIES COMPRISING PD-1 AND TGF-BRII BINDING DOMAINS | Non-Final OA | Incyte Corporation |
| 18266053 | MUTATIONS IN FELINE ANTIBODY CONSTANT REGIONS | Non-Final OA | Zoetis Services LLC |
| 18311108 | SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES | Non-Final OA | Hangzhou Qihan Biotech Co., Ltd. |
| 18336248 | METHOD FOR TREATING AUTOIMMUNE DISEASE USING CD4 T-CELLS WITH ENGINEERED STABILIZATION OF EXPRESSION OF ENDOGENOUS FOXP3 GENE | Non-Final OA | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18314077 | COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS | Non-Final OA | Janux Therapeutics, Inc. |
| 18303075 | METHODS AND COMPOSITIONS FOR CELLULAR THERAPY | Non-Final OA | Replay Holdings, Inc. |
| 17702648 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
| 17621978 | EGFR ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME | Non-Final OA | AMUNIX PHARMACEUTICALS, INC. |
| 17998527 | MULTISPECIFIC ANTIBODIES TARGETING CD38 AND BCMA AND USES THEREOF | Non-Final OA | Virtuoso BINco, Inc. |
| 17310463 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED CELLS FOR THE TREATMENT OF CLDN6-EXPRESSING CANCERS | Non-Final OA | BIONTECH CELL & GENE THERAPIES GMBH |
| 17486709 | Antibodies Directed Against Programmed Death-1 (PD-1) | Non-Final OA | ANAPTYSBIO, INC. |
| 17633439 | THERAPEUTIC USES OF ANTI-TCR DELTA VARIABLE 1 ANTIBODIES | Final Rejection | GAMMADELTA THERAPEUTICS LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy